FDA approves first biosimilar product for retinal diseases

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Study examines VR orientation, mobility testing for patients with inherited retinal diseases

Improvements are seen after gene therapy for Leber congenital amaurosis.

New sustained-release anti-VEGF formula proves safe and effective in phase 1 trials

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.